Lamotrigine clearance during pregnancy
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate changes in lamotrigine (LTG) clearance before, during, and after pregnancy. METHODS: Twelve pregnancies that had complete steady-state data before, during, and after pregnancy were evaluated. Data included weight, LTG dose, and LTG blood levels at preconception, during pregnancy, and postpartum, and concomitant use of other antiepileptic drugs and their dosages. Apparent clearance (L/[kg.day]) of LTG was calculated by dose/level/weight for time points at preconception; during the first trimester, second trimester, and third trimester; and postpartum. Apparent clearance was compared between preconception and each of the three trimesters. Statistical analysis was performed using one-way analysis of variance, the Student-Newman-Keuls test, and the paired Student's t-test. RESULTS: An increase in apparent clearance (>65%) was observed between preconception and the second and third trimesters (p < 0.05). Eleven pregnancies required higher doses of LTG to maintain therapeutic levels during pregnancy. There was no significant change in apparent clearance between each trimester. A decrease in apparent clearance was observed between the last two trimesters and postpartum (p < 0.05). In the postpartum period, apparent clearances returned to the preconception baseline, and LTG doses needed to be reduced. CONCLUSION: Pregnancy increases LTG clearance by >50%. This effect occurs early in pregnancy and reverts quickly after delivery. LTG levels should be monitored before, during, and after pregnancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cited by
Saving Mothers’ Lives: Reviewing maternal deaths to make motherhood safer: 2006–2008
(2011) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2010.02847.x · Cited by 2,994
Patsalos, P. N., Berry, D. J., Bourgeois, B. F. D., Cloyd, J. C., Glauser, T. A., Johannessen, S. I., Leppik, I. E., Tomson, T., & Perucca, E. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01561.x · Cited by 1,156
Self-citationPregnancy-Induced Changes in Pharmacokinetics: A Mechanistic-Based Approach
Anderson, G. D. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00001 · Cited by 648
Comparative safety of antiepileptic drugs during pregnancy
Hernández-Díaz, S., Smith, C. R., Shen, A., Mittendorf, R., Hauser, W. A., Yerby, M., Holmes, L. B., For the North American AED Pregnancy Registry, North American AED (Antiepileptic Drug) Pregnancy Registry, Cragan, J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182574f39 · Cited by 620
Sudden unexpected death in epilepsy
Shorvon, S., & Tomson, T. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60176-1 · Cited by 501
Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy
Tracy, T. S., Venkataramanan, R., Glover, D. D., & Caritis, S. N. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.08.030 · Cited by 448
Management of bipolar disorder during pregnancy and the postpartum period
Yonkers, K. A., Wisner, K. L., Stowe, Z., Leibenluft, E., Cohen, L., Miller, L., Manber, R., Viguera, A., Suppes, T., & Altshuler, L. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.608 · Cited by 394
“, a decrease in serum concentration) (57, 58).”
BackgroundYatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388
Abduljalil, K., Furness, P., Johnson, T. N., Rostami-Hodjegan, A., & Soltani, H. (2012) · Clinical Pharmacokinetics · doi:10.2165/11597440-000000000-00000 · Cited by 371
Lamotrigine and the risk of malformations in pregnancy
Cunnington, M., Tennis, P., & the International Lamotrigine Pregnancy Registry Scientific Advisory Committee (2005) · Neurology · doi:10.1212/01.wnl.0000154515.94346.89 · Cited by 348
Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review
Pariente, G., Leibson, T., Carls, A., Adams-Webber, T., Ito, S., & Koren, G. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002160 · Cited by 336
Seizure control and treatment in pregnancy: Observations from the EURAP Epilepsy Pregnancy Registry
The EURAP Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000195888.51845.80 · Cited by 331
Anderson, G. D. (2005) · Journal of Women's Health · doi:10.1089/jwh.2005.14.19 · Cited by 321
Harden, C. L., Pennell, P. B., Koppel, B. S., Hovinga, C. A., Gidal, B., Meador, K. J., Hopp, J., Ting, T. Y., Hauser, W. A., Thurman, D., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a6b325 · Cited by 307
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2004) · Epilepsy Research · doi:10.1016/j.eplepsyres.2004.07.010 · Cited by 300
Lamotrigine in pregnancy: Clearance, therapeutic drug monitoring, and seizure frequency
Pennell, P. B., Peng, L., Newport, D. J., Ritchie, J. C., Koganti, A., Holley, D. K., Newman, M., & Stowe, Z. N. (2008) · Neurology · doi:10.1212/01.wnl.0000289511.20864.2a · Cited by 291
ACOG Committee on Clinical Practice Guidelines–Obstetrics (2023) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000005202 · Cited by 252
Harden, C. L., Pennell, P. B., Koppel, B. S., Hovinga, C. A., Gidal, B., Meador, K. J., Hopp, J., Ting, T. Y., Hauser, W. A., Thurman, D., et al. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02130.x · Cited by 170
“Two Class II studies (Tran et al., 2002; Pennell et al., 2004) also showed an increase in the lamotrigine clearance.”
BackgroundAntiepileptic drugs in women with epilepsy during pregnancy
Gedzelman, E., & Meador, K. J. (2012) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098611433192 · Cited by 57
Metadata
- Authors
- Tran, T. A., Leppik, I. E., Blesi, K., Sathanandan, S. T., & Remmel, R.
- Venue
- Neurology
- Published
- 2002-07-23
- Volume
- 59
- Issue
- 2
- Pages
- 251-255
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2040710422
- Cited by
- 241
- References
- 1
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.